Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.

Despite Agilent Technologies’ strong performance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

MDT vs. A: Which Stock Is the Better Value Option?

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.

Agilent Technologies (NYSE:A) secured expanded European approval for its PD-L1 IHC 22C3 pharmDx test for ovarian cancer applications. The CE-marked indication now covers patients with ovarian, fallopian tube, and primary peritoneal carcinoma in the EU. The move strengthens Agilent's oncology diagnostics portfolio and supports wider use of targeted cancer therapies in Europe. For readers looking to explore more stocks tied to the rise of data driven tools in cancer care and diagnostics, a...

BioLife Solutions (BLFS) delivered earnings and revenue surprises of +500.00% and +1.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bronte Capital, an investment management company, released its “Amalthea Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund posted a 6.49% net return in June, bringing the quarterly returns to 5.12%, compared to 3.17% and 14.48% for the globally diverse MSCI ACWI in ($A), respectively. The outperformance in June […]

Envista (NVST) delivered earnings and revenue surprises of +24.24% and +2.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investors need to pay close attention to A stock based on the movements in the options market lately.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Kestra Medical Technologies, Ltd. (KMTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]

COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.

SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.

TMO lifted its 2026 outlook after Q2 topped estimates, driven by stronger demand, acquisitions and margin gains. Can the momentum continue?

TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.

Stryker (SYK) delivered earnings and revenue surprises of +6.65% and +0.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.

RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?

PHG lifts its 2026 profit and free cash flow outlook after Q2 earnings increase on higher sales, productivity gains and a U.S. tariff refund benefit.

Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.

SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.

DXCM's Q2 results may reflect strong G7 15 Day adoption, broader reimbursement, and expanding CGM demand as investors watch for continued double-digit revenue growth.

Agilent Technologies (A) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic for several OPDIVO based cancer treatments. See our latest analysis for Agilent Technologies. Agilent Technologies' recent FDA approval arrives as the stock trades at $138.57, with a 90 day share price return of 19.92% and a 1 year total shareholder return of 16.23%, indicating that momentum has strengthened in recent...

In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. This approval deepens Agilent’s role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in...

Agilent Technologies is poised to release its third-quarter results soon, and analysts are projecting a single-digit earnings rise.

GE HealthCare heads into Q2 earnings season with solid revenue drivers, but inflation and tariff costs may keep margins under pressure before an expected second-half recovery.

BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.

Over the past six months, Agilent’s stock price fell to $134.31. Shareholders have lost 8.2% of their capital, which is disappointing considering the S&P 500 has climbed by 8.4%. This may have investors wondering how to approach the situation.